APBI 2016

OncotypeDX (Genomic Health, USA)

HR+ / HER2- , T1-3, N-/N+ FFPE samples 21 GENES PROLIFERATION, ESTROGEN, HER2, INVASION (16 GENES) + REFS (5 GENES) CENTRALIZED RECURRENCE (10 years) BENEFIT TO ADJUVANT CT LOW RISK (RS<18):

+ HT / NO CHEMOTHERAPY INTERMEDIATE: DISCUSSION HIGH RISK (RS≥31): +HT / + CHEMOTHERAPY